Introduction {#sec1}
============

The emergence and spread of drug-resistant bacteria have always been a public concern. With the increase of resistance to available antimicrobial agents and the emergence of multi-drug resistant bacteria, antimicrobial resistance has caused serious threats to public health in the world ([@bib13]; [@bib21]; [@bib29]). It can cause damage to human health and, at the same time, it can lead to a situation where there is no cure. The research reported that antimicrobial resistance causes about 700 000 deaths worldwide each year, and if no effective action is taken, it is expected to cause 10 million deaths a year by 2050 ([@bib5]).

Simultaneously, antibiotics that become ineffective against bacteria have been reported ([@bib12]). The bacterial resistance crisis has been greatly attributed to the overuse and misuse of these antibiotics ([@bib17]; [@bib14]; [@bib24]). Monitoring of the epidemiology of resistance provides useful information for prevention and helps clinicians prescribe the effective antibiotic therapy ([@bib25]), as well as optimize the use of antibiotics, which has become one of the most important parts of drug resistance control ([@bib11]; [@bib28]). In this study, the significant changes and trends in antibiotic resistance of clinically important pathogens isolated from a general hospital in Zhengzhou, Henan Province, China, from 2011 to 2016 were described to provide a more complete picture of bacterial infections and to help clinicians and decision-making departments undertake the proper decisions for patients and antibiotic use.

Experimental {#sec2}
============

Materials and Methods {#sec3}
---------------------

Based on the data from a general hospital in Zhengzhou, Henan province, China from 2011 to 2016, five dominant bacteria (*Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa*, and *Acinetobacter baumannii*) were investigated in this study. The antibiotic susceptibilities of the isolates were determined using the broth dilution method according to [@bib4]. In this study, the intermediate was attributed as the resistant. The differences in proportions were compared using the chi-squared test and the variation tendency was compared using the chi-squared for trend. Two-sided test with *p* \< 0.05 were taken as statistically significant, with the use of SAS 9.1.

Results {#sec4}
=======

From 2011 to 2016, a total of 19 260 bacterial isolates were obtained, with five dominant bacteria being *K. pneumoniae* (17.71%), *E. coli* (14.45%), *S. aureus* (7.42%), *P. aeruginosa* (6.64%), and *A. baumannii* (5.75%). Overall, these isolates accounted for 51.98% of all reported isolates. Also, a wavy increase was observed in the detection rates of these isolates (Table [I](#tbl1){ref-type="table"}).

###### 

Distribution of bacterial isolates in relation to years and type of samples.

![](pjm-68-2-225-t001)

  Category       No. isolates   *Klebsiella pneumoniae*   *Escherichia coli*   *Staphylococcus aureus*   *Pseudomonas aeruginosa*   *Acinetobacter baumannii*   Total                                          
  -------------- -------------- ------------------------- -------------------- ------------------------- -------------------------- --------------------------- --------- ------- ----------- ------- -------- -------
  Year                                                                                                                                                                                                         
  2011           1429           276                       19.31                213                       14.91                      96                          6.72      108     7.56        68      4.76     761
  2012           3350           524                       15.64                531                       15.85                      248                         7.40      236     7.04        114     3.40     1653
  2013           3143           486                       15.46                493                       15.89                      219                         6.98      168     5.35        114     3.63     1480
  2014           3073           605                       19.69                477                       15.52                      213                         6.93      248     8.07        224     7.29     1767
  2015           3750           781                       20.83                522                       13.92                      254                         6.77      259     6.91        292     7.89     2108
  2016           4515           739                       16.37                548                       12.18                      400                         8.86      259     5.74        296     6.56     2242
  Total          19260          3411                      17.71                2784                      14.45                      1430                        7.42      1278    6.64        1108    5.75     10011
  *χ*^2^         1.5767                                   −4.7904                                        2.5513                                                 −1.7311           7.8954              1.9893   
  *p*            0.1149                                   \< 0.0001                                      0.0107                                                 0.0834            \< 0.0001           0.0467   
  Samples                                                                                                                                                                                                      
  Sputum         2741           80.36                     493                  17.71                     81                         5.66                        1023      80.05   910         82.13   5248     27.25
  Urine          382            11.2                      1565                 56.21                     249                        17.41                       110       8.61    87          7.85    2393     12.42
  Blood          104            3.05                      265                  9.52                      275                        19.23                       30        2.35    24          2.17    698      3.62
  Secretion      92             2.7                       217                  7.79                      620                        43.36                       65        5.09    41          3.70    1035     5.37
  Throat swabs   27             0.79                      8                    0.29                      6                          0.42                        3         0.23    3           0.27    47       0.24
  Others         65             1.91                      236                  8.48                      199                        13.92                       47        3.68    43          3.88    590      3.06

During the study period, the detection rate of *K. pneumoniae* isolates was stable, meanwhile, the rate of extended-spectrum beta-lactamase (ESBL)-producing *K. pneumoniae* (ESBL-*K. pneumoniae*) showed a downward trend (χ^2^ = -- 4.6619, *p* \< 0.0001). A significant increase of resistance was observed for cefotaxime, meropenem, and imipenem to *K. pneumoniae* and ESBL-*K. pneumoniae*. But a significant decrease of resistance was seen for nitrofurantoin. Beyond that, the resistance rates of ampicillin, levofloxacin, cefepime, and piperacillin-tazobactam against *K. pneumoniae* increased from 97.1% to 100%, from 34.42% to 35.05%, from 23.91% to 34.91%, and from 21.74% to 30.58%, respectively. In addition, the rate of trimethoprim-sulfamethoxazole decreased from 71.38% to 55.07%. These results are shown in Table [II](#tbl2){ref-type="table"} and Table S-I. The resistance rates of ESBL-*K. pneumoniae* isolates to cefuroxime, ceftriaxone, ampicillin-sulbactam, trimethoprim-sulfamethoxazole, gentamicin, cefotaxime, cefepime, nitrofurantoin, levofloxacin were higher than the rates displayed by ESBL-negative *K. pneumoniae* isolates (*p* \< 0.05) (Table S-II).

###### 

The resistance rates of *K. pneumoniae* to 15 antimicrobial agents in the years 2011 to 2016.
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  Antimicrobial agent             MIC breakpoints   2011    2012    2013    2014    2015    2016    Total   *χ*^2^    *p*
  ------------------------------- ----------------- ------- ------- ------- ------- ------- ------- ------- --------- -----------
  Ampicillin                      16                97.1    99.05   98.97   99.5    100     100     99.38   5.2285    \< 0.0001
  Cefotaxime                      2                 52.17   54.39   45.27   56.86   100     100     73.67   26.9374   \< 0.0001
  Nitrofurantoin                  64                76.81   65.84   49.59   56.36   54.16   58.59   58.49   −4.711    \< 0.0001
  Trimethoprim-sulfamethoxazole   4/76              71.38   70.61   52.06   35.7    37      55.07   50.78   −9.1411   \< 0.0001
  Ampicillin-sulbactam            16/8              52.54   49.81   46.09   40.17   47.25   47.9    46.79   −1.1923   0.2332
  Cefuroxime                      16                50.72   49.81   43.21   42.64   47.76   51.01   47.46   0.51      0.6101
  Ceftriaxone                     2                 48.91   53.24   43.21   37.52   46.09   48.71   46.06   −0.9744   0.3299
  Gentamicin                      8                 44.93   43.7    33.74   31.74   40.46   40.46   38.82   −0.8754   0.3813
  Cefoxitin                       16                40.58   43.51   34.77   31.9    39.44   39.51   38.17   −0.6514   0.5148
  Levofloxacin                    4                 34.42   33.21   22.02   26.12   37.26   35.05   31.78   2.3291    0.0199
  Cefepime                        16                23.91   33.59   22.84   26.28   35.47   34.91   30.69   3.7816    0.0002
  Piperacillin-tazobactam         32/4--64/4        21.74   24.81   18.93   23.64   32.01   30.58   26.41   4.7683    \< 0.0001
  Amikacin                        32                26.09   26.53   16.05   18.02   28.55   23      23.19   0.376     0.7069
  Meropenem                       2                 0       0       0       0.99    10.12   11.37   4.95    12.3843   \< 0.0001
  Imipenem                        2                 0       0       0       1.49    9.22    7.98    4.1     10.4364   \< 0.0001

During the study period, the detection rates of *E. coli* and ESBL-producing *E. coli* (ESBL-*E. coli*) showed a declining trend (χ^2^ = -- 4.7904, *p* \< 0.0001 and χ^2^ = -- 2.1785, *p* = 0.0294, respectively). A significant increase of resistance against *E. coli* and ESBL-*E. coli* was observed for cefotaxime, ceftazidime, and meropenem. But a significant decrease of resistance was seen for trimethoprim-sulfamethoxazole, ampicillin-sulbactam, gentamicin, cefepime, cefoxitin, nitrofurantoin, and amikacin. A marked decrease of resistance against *E. coli* was observed for cefuroxime and ceftriaxone, i.e., from 70.42% to 62.59%, and from 69.01% to 62.23%, respectively. However, the resistance rates of these two antimicrobial agents to ESBL-*E. coli* showed an increasing trend (both from 95.6% to 100%). All the ESBL-*E. coli* isolates were resistant to ampicillin. These data are presented in Table [III](#tbl3){ref-type="table"} and Table S-III. The resistance rates of ESBL-*E. coli* isolates to ceftriaxone, cefuroxime, ampicillin-sulbactam, cefepime, ampicillin, cefotaxime, levofloxacin, ceftazidime, gentamicin, and trimethoprim-sulfamethoxazole were higher than the rates of the ESBL-negative *E. coli* isolates (*p* \< 0.05) (Table S-IV).

###### 

The resistance rates of *E. coli* to 16 antimicrobial agents in the years 2011 to 2016.

![](pjm-68-2-225-t003)

  Antimicrobial agent             MIC breakpoints   2011    2012    2013    2014    2015    2016    Total   *χ*^2^     *p*
  ------------------------------- ----------------- ------- ------- ------- ------- ------- ------- ------- ---------- -----------
  Ampicillin                      16                92.49   93.03   90.06   86.37   87.16   88.87   89.4    −3.0413    0.0024
  Cefotaxime                      2                 69.01   72.88   71.4    73.17   100     100     82.79   16.5655    \< 0.0001
  Trimethoprim-sulfamethoxazole   4/76              93.9    93.03   81.74   77.99   70.69   69.16   79.63   −11.9199   \< 0.0001
  Ampicillin-sulbactam            16/8              76.06   73.63   80.53   67.92   60.15   62.96   69.43   −6.7117    \< 0.0001
  Cefuroxime                      16                70.42   73.45   71.81   67.51   60.92   62.59   67.42   −4.8433    \< 0.0001
  Levofloxacin                    4                 73.71   71.56   67.95   65.62   66.67   61.13   67.1    −4.0714    \< 0.0001
  Ceftriaxone                     2                 69.01   72.5    68.97   64.36   60.15   62.23   65.88   −4.3853    \< 0.0001
  Gentamicin                      8                 74.18   65.73   60.45   59.75   51.34   52.92   59.2    −6.7725    \< 0.0001
  Cefepime                        16                49.77   54.24   46.25   38.36   30.65   38.32   42.21   −7.1678    \< 0.0001
  Ceftazidime                     8                 17.84   1.32    48.48   43.61   34.29   36.31   31.25   9.9654     \< 0.0001
  Cefoxitin                       16                30.52   29.57   29.41   21.17   12.07   10.77   21.19   −10.1704   \< 0.0001
  Nitrofurantoin                  64                28.17   27.31   16.02   14.47   10.73   11.13   16.88   −8.6556    \< 0.0001
  Piperacillin-tazobactam         32/4-64/4         14.55   18.64   13.18   13.63   6.7     10.77   12.72   −4.6131    \< 0.0001
  Amikacin                        32                18.31   15.25   10.75   8.39    8.24    8.03    10.78   −5.3067    \< 0.0001
  Imipenem                        2                 0.94    1.51    2.43    1.26    1.15    1.64    1.54    −0.1060    0.9156
  Meropenem                       2                 0       0.56    0.2     1.05    0.96    2.01    0.9     3.1604     0.0016

During the study period, the detection rate of *S. aureus* showed an upward trend (χ^2^ = 2.5513, *p* = 0.0107), meanwhile, the rate of methicillin-resistant *S. aureus* (MRSA) was stable. A significant decrease of resistance of isolates of *S. aureus* (including MRSA) was observed for erythromycin, azithromycin, clarithromycin, trimethoprim-sulfamethoxazole, clindamycin, cefoxitin, norfloxacin, moxifloxacin, gentamicin, tetracycline, rifampicin, nitrofurantoin, and teicoplanin. No *S. aureus* isolate was found to be resistant to linezolid and vancomycin. All MRSA isolates were resistant to oxacillin. These results are depicted in Table [IV](#tbl4){ref-type="table"} and Table S-V. The resistance rates of MRSA to 15 antimicrobial agents were higher than that of methicillin-susceptible *S. aureus* (MSSA) (*p* \< 0.05) (Table S-VI).

###### 

The resistance rates of *S. aureus* to 18 antimicrobial agents in the years 2011 to 2016.
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  Antimicrobial agent             MIC breakpoints   2011    2012    2013    2014    2015    2016    Total   *χ*^2^    *p*
  ------------------------------- ----------------- ------- ------- ------- ------- ------- ------- ------- --------- -----------
  Penicillin                      0.25              92.71   93.55   94.06   95.77   88.19   89.00   91.68   −2.759    0.0058
  Erythromycin                    1--4              95.83   87.10   80.82   80.28   82.28   81.00   83.15   −3.0012   0.0027
  Azithromycin                    4                 90.63   86.29   80.37   81.22   77.95   76.50   80.70   −3.8879   0.0001
  Clarithromycin                  4                 90.63   83.87   79.45   79.81   70.08   69.00   76.43   −6.0151   \< 0.0001
  Trimethoprim-sulfamethoxazole   4/76              85.42   91.13   62.56   69.95   73.62   51.25   68.95   −9.9209   \< 0.0001
  Clindamycin                     1-2               67.71   65.73   59.36   56.34   55.12   58.25   59.51   −2.4495   0.0143
  Cefoxitin                       8                 69.79   72.18   71.23   58.69   44.49   41.50   56.36   −9.6125   \< 0.0001
  Norfloxacin                     8                 70.83   64.11   63.01   59.62   52.36   43.75   55.94   −6.6063   \< 0.0001
  Levofloxacin                    2                 67.71   61.29   57.99   56.34   48.43   36.25   51.19   −7.6331   \< 0.0001
  Moxifloxacin                    1                 63.54   56.45   52.51   53.99   48.03   34.50   48.32   −6.5328   \< 0.0001
  Gentamicin                      8                 64.58   64.11   46.12   45.54   35.83   35.00   45.45   −8.242    \< 0.0001
  Tetracycline                    8                 58.33   57.26   47.49   47.42   38.98   37.00   45.45   −5.9025   \< 0.0001
  Oxacillin                       4                 53.13   42.74   33.79   43.66   45.67   42.25   42.59   −0.6128   0.8283
  Rifampicin                      2                 40.63   30.65   25.57   21.60   17.32   10.00   21.19   −8.1147   \< 0.0001
  Nitrofurantoin                  64                26.04   15.73   16.44   9.86    5.91    8.00    11.75   −5.7483   \< 0.0001
  Teicoplanin                     16                11.46   12.10   5.02    4.23    0.79    1.75    4.90    −6.6928   \< 0.0001
  Linezolid                       8                 0       0       0       0       0       0       0                  
  Vancomycin                      4--8              0       0       0       0       0       0       0                  

During the study period, the detection rate of *P. aeruginosa* was stable. A significant decrease of resistance was observed for gentamicin, tobramycin, and polymyxin B from 52.78% to 50.58%, from 53.7% to 44.4%, and from 20.37% to 6.56%, respectively. In addition, a marked increase was seen for meropenem from 44.44% in 2011 to 49.81% in 2016 (Table [V](#tbl5){ref-type="table"}).

###### 

The resistance rates of *P. aeruginosa* to 13 antimicrobial agents in the years 2011 to 2016.
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  Antimicrobial agent       MIC breakpoints   2011    2012    2013    2014    2015    2016    Total   *χ*^2^    *p*
  ------------------------- ----------------- ------- ------- ------- ------- ------- ------- ------- --------- -----------
  Ticarcillin               32-64             70.37   74.58   76.79   76.21   75.29   76.45   75.35   0.9182    0.3585
  Piperacillin              32-64             57.41   63.14   54.76   56.45   61.00   61.39   59.47   0.3942    0.6934
  Imipenem                  4                 50.00   52.97   60.71   53.63   62.16   57.92   56.73   1.8507    0.0642
  Aztreonam                 16                50.93   48.31   54.76   50.00   52.90   54.83   51.96   1.1464    0.2516
  Gentamicin                8                 52.78   61.02   55.36   43.95   49.42   50.58   51.80   −2.2516   0.0243
  Ceftazidime               16                43.52   52.54   54.76   49.19   51.74   53.28   51.41   0.8686    0.3851
  Tobramycin                8                 53.70   58.90   52.38   39.11   49.81   44.40   48.98   −3.0892   0.0020
  Piperacillin-tazobactam   32/4--64/4        43.52   51.27   42.86   41.94   52.90   53.28   48.44   1.6789    0.0932
  Norfloxacin               8                 50.93   54.24   47.02   39.92   48.26   48.26   47.81   −1.2309   0.2183
  Meropenem                 4                 44.44   41.95   45.24   45.16   54.44   49.81   47.34   2.4052    0.0162
  Cefepime                  16                42.59   46.19   50.60   37.90   49.81   51.74   46.71   1.5010    0.1334
  Ciprofloxacin             2                 48.15   52.97   45.83   41.53   45.56   44.02   46.09   −1.7609   0.0783
  Levofloxacin              4                 45.37   47.88   40.48   37.90   45.95   45.95   43.97   −0.0615   0.9510
  Amikacin                  32                36.11   40.68   37.50   29.03   35.52   36.29   35.68   −0.9114   0.3621
  Polymyxin B               4                 20.37   19.49   14.29   9.68    13.51   6.56    13.15   −4.5199   \< 0.0001

During the study period, the detection rate of *A. baumannii* showed an increasing tendency (χ^2^ = 7.8954, *p* \< 0.0001). A significant increase of resistance of the isolates was observed for ceftriaxone, gentamicin, ciprofloxacin, ceftazidime, trimethoprim-sulfamethoxazole, cefepime, levofloxacin, piperacillin-tazobactam, and amikacin (Table [VI](#tbl6){ref-type="table"}).

###### 

The resistance rates of *A. baumannii* to 13 antimicrobial agents in the years 2011 to 2016.
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  Antimicrobial agent             MIC breakpoints   2011    2012    2013    2014    2015    2016    Total   *χ*^2^    *p*
  ------------------------------- ----------------- ------- ------- ------- ------- ------- ------- ------- --------- -----------
  Ceftriaxone                     16--32            32.35   64.04   72.81   72.77   79.11   80.74   73.19   7.4412    \< 0.0001
  Ampicillin-sulbactam            16/8              41.18   64.91   81.58   76.79   73.63   64.53   69.77   1.5591    0.1190
  Gentamicin                      8                 44.12   67.54   64.04   74.55   68.15   75.68   69.49   4.0867    \< 0.0001
  Ciprofloxacin                   2                 39.71   57.89   64.04   73.66   69.52   75.34   68.32   5.6165    \< 0.0001
  Ceftazidime                     16                39.71   52.63   64.04   66.07   62.67   72.64   63.72   5.0871    \< 0.0001
  Trimethoprim-sulfamethoxazole   4/76              39.71   63.16   60.53   60.27   66.78   64.86   62.27   3.0414    0.0024
  Cefepime                        16                35.29   50.00   56.14   62.05   61.99   70.95   60.92   5.8829    \< 0.0001
  Levofloxacin                    4                 41.18   53.51   64.04   65.18   59.93   64.53   60.83   2.9341    0.0033
  Piperacillin-tazobactam         32/4--64/4        29.41   50.00   57.02   58.04   64.38   68.24   59.75   6.0938    \< 0.0001
  Amikacin                        32                33.82   60.53   56.14   62.50   57.53   62.84   58.66   2.8410    0.0045
  Meropenem                       4                 19.12   46.49   57.89   54.02   47.95   47.64   48.19   1.9045    0.0568
  Imipenem                        4                 20.59   48.25   61.40   59.38   45.55   37.16   46.48   −1.0354   0.3005
  Polymyxin B                     4                 10.29   21.93   15.79   19.64   13.63   18.24   16.88   0.0504    0.9598

Discussion {#sec5}
==========

This study provided data about detection rates and resistance patterns of five dominant bacteria isolated in a general hospital in Zhengzhou, Henan province, China, between 2011 and 2016. Overall, the detection rates of these bacteria showed a slowly increasing trend. In addition, Gram-negative bacteria seemed to be the main cause of infection. The possible explanation of these phenomena could be the overrepresentation of some types of the samples (sputum and urine), or a double-membrane structure and the occurrence of efficient efflux pumps in Gram-negative bacteria ([@bib2]). Several studies have reported similar findings. The data from CHINET surveillance between 2005 and 2014 showed that the five selected species, including *E. coli, K. pneumoniae, P. aeruginosa, A. baumannii*, and *S. aureus* accounted for 51.9 to 60.3% of all isolates ([@bib8]). In a four-year study in Italy, researchers found that Gram-negative bacteria appeared to be the major causes of infection ([@bib19]). Thus, in terms of quantity and proportion, Gram-negative bacteria have become a major threat in nosocomial infections.

During the study period, the situation with these multi-resistant isolates was complicated. For *K. pneumoniae* and *A. baumannii*, the rates of multi-resistant isolates were increasing. For *E. coli, P. aeruginosa*, and *S. aureus*, the rates were decreasing. From these results, one can get directions for making recommendations by some government policies, such as separation the clinic from the pharmacy, hospital surveillance and preventive measures. All these recommendations may have played a role in combating antibiotic resistance. But more importantly, a problem demanding prompt solution is how to prevent the spread of multi-drug resistant isolates and how to optimize the use of the existing antibiotics.

Overall, among the Enterobacteriaceae, 14.34% of *K. pneumoniae* isolates and 50.18% of *E. coli* isolates were ESBL producers. A marked decrease in the detection rates was seen for ESBL-*K. pneumoniae* and ESBL-*E. coli*. In addition, the resistance rates of ESBL-positive isolates to multiple antibiotics (mainly cephalosporin antibiotics) were higher than that of ESBL-negative isolates. This might be related to the extensive use of cephalosporin in clinical practice, especially the third generation cephalosporin ([@bib17]; [@bib24]). But the resistance rate of ESBL-positive isolates to cefoxitin was lower than that of ESBL-negative isolates. Also, the resistance rate of these isolates to cefoxitin was lower than that to the third generation cephalosporin. In the absence of details about the resistance genes of these isolates, we could not infer that this was related to *AmpC*. Moreover, the ESBL-positive isolates were not only resistant to cephalosporin antibiotics, but also resistant to fluoroquinolones. As observed in this study, the resistance rate of ESBL-*K. pneumoniae* and ESBL-*E. coli* to levofloxacin was 37.22% and 79.10%, with a marked increase, respectively. This has led to growing utilization of carbapenems. Fortunately, the majority of *K. pneumoniae* and *E. coli* were sensitive to carbapenems ([@bib8]; Khan et al. 2017; [@bib29]).

Although the resistance rate of *S. aureus* to most antibiotics was declining, the resistance rate of the isolates was still above 40%. This indicated the severity of multidrug resistance in *S. aureus*. This phenomenon was more pronounced in MRSA. During the study period, the detection rate of MRSA was 42.38%. The data from CHINET surveillance showed a marked decrease of MRSA from 69% in 2005 to 44.6% in 2014 ([@bib8]). The resistance rate of MRSA to antibiotics was apparently higher than that of MSSA, except linezolid and vancomycin. This was associated with SCC*mec* elements. The SCC*mec* element is a mobile genetic element that carries a variety of antibiotic resistance genes, such as drug-resistance genes against mercury, cadmium, kanamycin, bleomycin, erythromycin, spectinomycin, and fusidic acid ([@bib9]; [@bib7]). Currently, vancomycin is still an ideal antibiotic to treat *S. aureus*-related infections, but vancomycin-resistant *S. aureus* has been reported ([@bib16]; [@bib27]; [@bib15]).

In this study, besides polymyxin B, *P. aeruginosa* showed high resistance to other antibiotics. The emergence of multidrug-resistant *P. aeruginosa* posed a difficult problem for clinical treatment ([@bib26]). Compared with the data from CHINET, the resistance rate of *P. aeruginosa* to nine antibiotics (imipenem, meropenem, gentamicin, ceftazidime, tobramycin, pipe ra cillin-tazobactam, cefepime, ciprofloxacin, levofloxacin, and amikacin) in this study were higher than in the surveillance data, which might be related to differences among the surveillance area ([@bib8]). Aminoglycosides are recognized for their efficacy against *P. aeruginosa* ([@bib6]). Although the resistance rate of *P. aeruginosa* to aminoglycoside antibiotics was decreasing, the strains showed high levels of resistance. For example, the antibiotic with the lowest resistance rate was amikacin, which resistance rate was 35.68%. Meanwhile, *P. aeruginosa* also showed high resistance to carbapenems, which might be related to the high use of these antibiotics in clinics.

A similar trend was observed for *A. baumannii*, and more seriously, the detection rate of isolates and the resistance rate of isolates to the majority of antibiotics were increasing. These were consistent with other studies ([@bib18]). This was mainly due to the membrane impermeability of *A. baumannii*, which leads to difficulty in traversing the membrane and reaching their targets by antibiotics ([@bib22]; [@bib30]). Carbapenem antibiotics are important for the treatment the *A. baumannii* infection, but reports have shown that the rate of carbapenems-resistant *A. baumannii* was increasing ([@bib1]; [@bib8]). Research had shown that the increasing use of carbapenems was associated with the increasing rate of carbapenem-resistant *A. baumannii* ([@bib23]). This showed the importance of rational use of antibiotics. [@bib20] had shown a benefit of combination monotherapy with polymyxin B for severe extensively drug-resistant *A. baumannii* or *P. aeruginosa* infections. Resistance to polymyxin B would increase the difficulty of treating multi-drug resistant *A. baumannii* and *P. aeruginosa*. [@bib3] have developed a new combination therapy using minimal concentrations of polymyxin B.

Conclusions {#sec6}
===========

In conclusion, Gram-negative bacteria appeared to be the main cause of infection in this study. The resistance rates of five species of the bacteria to most antibiotics were decreasing, but the isolates showed high levels of resistance and multiple-drug resistance, especially *P. aeruginosa* and *A. baumannii*. Methods such as the combination of antibiotics to optimize the use of antibiotics may help to solve the problem. Simultaneously, this study showed that some antibiotics continue to be active against these isolates, such as meropenem and imipenem for ESBL-*K. pneumoniae* and ESBL-*E. coli*, linezolid and vancomycin for MRSA and polymyxin B for *P. aeruginosa*, and *A. baumannii*. The mobility of modern society is unprecedented. Geographical boundaries cannot stop the spread of drug-resistant bacteria.
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Limitation {#sec9}
==========

Our study has several limitations. First, we do not know the use of antibiotics in patients from whom the bacteria were isolated, nor their outcomes. Second, we did not track the changes of these strains at the genetic level in the laboratory.
